GNFTF Stock - Genfit S.A.
Unlock GoAI Insights for GNFTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $67.00M | $28.57M | $20.20M | $80.07M | $765,000 |
| Gross Profit | $66.70M | $28.22M | $19.95M | $79.91M | $563,000 |
| Gross Margin | 99.6% | 98.8% | 98.8% | 99.8% | 73.6% |
| Operating Income | $3.28M | $-26,580,000 | $-27,289,000 | $31.82M | $-82,897,000 |
| Net Income | $1.51M | $-28,894,000 | $-23,720,000 | $67.26M | $-101,221,000 |
| Net Margin | 2.2% | -101.2% | -117.5% | 84.0% | -13231.5% |
| EPS | $0.03 | $-0.58 | $-0.48 | $1.50 | $-2.60 |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Visit WebsiteEarnings History & Surprises
GNFTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q3 2025 | Sep 22, 2025 | $1.21 | $-0.24 | -119.5% | ✗ MISS |
Q2 2025 | May 22, 2025 | — | — | — | — |
Q2 2025 | Apr 24, 2025 | $-0.24 | $-0.58 | -138.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | — | — | — | — |
Q3 2024 | Sep 19, 2024 | $0.33 | $0.50 | +51.2% | ✓ BEAT |
Q2 2024 | May 14, 2024 | — | — | — | — |
Q2 2024 | Apr 4, 2024 | $1.35 | $-0.16 | -112.0% | ✗ MISS |
Q4 2023 | Dec 30, 2023 | — | $-0.14 | — | — |
Q3 2023 | Sep 20, 2023 | $-0.39 | $-0.42 | -7.6% | ✗ MISS |
Q2 2023 | Apr 13, 2023 | $-1.08 | $-0.27 | +75.2% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q3 2022 | Sep 28, 2022 | $-0.23 | $-0.21 | +9.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.90 | $1.46 | +262.6% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.79 | $1.02 | +229.1% | ✓ BEAT |
Q1 2022 | Jan 24, 2022 | — | — | — | — |
Q3 2021 | Sep 29, 2021 | $-1.20 | $0.19 | +115.9% | ✓ BEAT |
Q2 2021 | May 12, 2021 | — | — | — | — |
Q2 2021 | Apr 1, 2021 | $-0.86 | $-1.24 | -44.5% | ✗ MISS |
Q4 2020 | Nov 16, 2020 | — | — | — | — |
Latest News
Frequently Asked Questions about GNFTF
What is GNFTF's current stock price?
What is the analyst price target for GNFTF?
What sector is Genfit S.A. in?
What is GNFTF's market cap?
Does GNFTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GNFTF for comparison